Navigation Links
Agendia Expands Laboratory Capacity at New Amsterdam Headquarters to Meet Increasing Demand for Services Worldwide
Date:6/19/2008

AMSTERDAM, The Netherlands, June 19 /PRNewswire/ -- Agendia BV has announced the official opening of the company's new headquarters yesterday at Amsterdam's Science Park at Watergraafsmeer, Kruislaan 406. The Grand Opening ceremony was officiated by Dr. Rene Bernards, Chief Scientific Officer at Agendia and the Honourable Director General Mrs. R.M. Bergkamp, on behalf of the Honourable Mrs. Maria van der Hoeven, Minster of Economic Affairs for The Netherlands.

"Agendia has a distinguished history of providing exceptional high quality diagnostic testing services that provide valuable information for cancer patients and the physicians who treat them," said Dr. Bernhard Sixt, Agendia's president & chief executive officer (CEO). "The expanded capacity of our laboratories at our new location will allow us to meet the growing worldwide demand for our clinical services as we expand into major markets, enhancing the company's ability to serve the healthcare community."

The new facilities offer 13,000 square feet of laboratory and office space that will support the company's molecular diagnostic cancer testing services and research activities.

"Additionally, this move proves our ability to replicate our FDA-cleared and CLIA-certified laboratory in a new location in just 4 months," said Dr. Jan Groen, vice president and chief operating officer (COO) at Agendia. "The increased laboratory space will also allow the company to expand our research and product development capabilities to enhance commercialization of emerging diagnostic discoveries in cancer."

Currently, Agendia offers three test services through its expanded laboratories, including MammaPrint(R), based on the Amsterdam 70-gene profile that indicates risk of recurrence for breast cancer tumors and the first in vitro diagnostic multi index variant assay (IVDMIA) cleared by the U.S. Food and Drug Administration (FDA), and CupPrint(R), which identifies the origin of metastases with unknown primary tumors (Cancer of Unknown Primary).

About Agendia

Agendia, located in Amsterdam, The Netherlands, is a world leader in gene expression analysis-based diagnostics with three products on the market. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first company to commercialize a prognostic test -- MammaPrint(R) -- that predicts the risk of breast cancer recurrence. Agendia maintains close ties with several leading academic centers to develop state of the art diagnostic tests for cancer. Agendia also offers its expertise to pharma companies focusing on development of highly effective personalized drugs in the area of oncology. For more information on Agendia, please visit http://www.agendia.com.

* CupPrint(R) is based on a license to the TUO database of AviaraDx

For Agendia - EU & non-U.S.-based Media:

Dr. Bernhard Sixt

President and Chief Executive Officer

Agendia

+31204621520

communications@agendia.com

For Agendia - U.S. Media:

Kelly Connor

Vice President

Ogilvy Public Relations Worldwide

+1.212.880.5328 Office

+1.609.221.5785 Mobile

Kelly.connor@ogilvypr.


'/>"/>
SOURCE Agendia BV
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Time Magazine Names Agendia Test a Best Invention of 2007
2. Agendias MammaPrint(R), the Only FDA-Cleared Breast Cancer Prognosis Test, is Now Widely Available to U.S. Patients
3. Agendia Appoints Oncologist Richard A. Bender as Vice President and Chief Medical Officer
4. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
5. Rohm and Haas Expands in India
6. Concentra Expands Horizon Air Employee Health Program With On-Site Clinic
7. Regional Center of Orange County Expands Family Support Resources to Meet Growing Needs
8. Maimonides Expands Circulation of Physicians Practice Journal to Staten Island Doctors
9. Specialty Blades, Inc. Expands Management Team With New VP Engineering
10. CRH Medical expands Las Vegas operations
11. US Med-Equip Expands Corporate Support Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... 2016 , ... It is vital for any lab to secure funding, and ... team at Beckman Coulter has designed Kaluza, templates with advanced analytical tools to streamline ... operate in a GLP (Good Laboratory Practice) fashion. , With features designed to simplify ...
(Date:12/7/2016)... ... ... came time to blow out his candles on his 14th birthday, Estefano Reano had only ... team at Joe DiMaggio Children’s Hospital surprised his family with a phone call that made ... , “He was playing at home, when we got the phone call telling us there ...
(Date:12/7/2016)... ... ... One of two inventors from Glen Burnie, Md., has a granddaughter who ... is why the co-inventor and I have designed a new and better way to ... of the patent-pending AV-AIR, a device that serves as an alternative to conventional methods ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... that its fully redesigned website, which launched October 17, 2016, features comprehensive information ... design and easy-to-navigate layout. Visitors and patients can discover the latest clinical dermatology ...
(Date:12/7/2016)... City, CA (PRWEB) , ... December 07, 2016 , ... ... during the holidays and winter seasons. One major study analyzing heart attacks among ... compared to August of a given year. We would all agree of course–no time ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... PARK , Israel , December 7, 2016 ... today the signing of a memorandum of understanding with Korean company ... between the companies will assist in expediting Kadimastem,s entry into international ... innovative treatment for severe diseases in general and ALS and diabetes ... , , ...
(Date:12/7/2016)... , Dec. 7, 2016 Boehringer Ingelheim ... in patients with unresectable malignant pleural mesothelioma (MPM) ... The data, presented at the 17 th ... Vienna , showed nintedanib plus pemetrexed/cisplatin ... plus pemetrexed/cisplatin, with a significantly improved PFS (9.4 ...
(Date:12/7/2016)... , Dec. 7, 2016  Ionis Pharmaceuticals, Inc. (NASDAQ: ... will present a company overview at the BMO Capital Markets Prescriptions ... New York, NY . A live webcast of ... of the Ionis website.  The replay will be available within 48 ... ...
Breaking Medicine Technology: